Dystrophic Epidermolysis Bullosa Treatment Market: Introduction
According to the report, the global dystrophic epidermolysis bullosa treatment market was valued over US$ 412 Mn in 2019 and is projected to expand at a CAGR of ~5% from 2020 to 2030. Dystrophic epidermolysis bullosa (DEB) is the second most common form of epidermolysis bullosa. The prevalence of DEB varies from 1 per 49,000 inhabitants in Scotland to 1 per 420,168 in the U.S. According to the U.S. National Library of Medicine, the prevalence of recessive and dominant dystrophic epidermolysis bullosa is estimated at 3.3 per million people. North America dominated the global dystrophic epidermolysis bullosa treatment market in 2019 and the trend is anticipated to continue during the forecast period. The rise in population suffering from various diseases in North America has increased the number of patients visiting hospitals. Hence, the consumption of dystrophic epidermolysis bullosa treatment products is expected to increase during the forecast period. North America’s large share of the global dystrophic epidermolysis bullosa treatment market can be attributed to high cost of biologic drugs compared to other regions. It is a key target region for all players in the global dystrophic epidermolysis bullosa treatment market. Asia Pacific is likely to be a highly lucrative market for dystrophic epidermolysis bullosa treatment from 2020 to 2030. The market in the region is projected to expand at a high CAGR during the forecast period.
Request Brochure for Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=79063
Antibiotics to Dominate Global Market
In terms of treatment type, the global dystrophic epidermolysis bullosa treatment market has been classified into antibiotics, corticosteroids, opioid analgesics, anticonvulsant, and others. The antibiotics segment dominated the global dystrophic epidermolysis bullosa treatment market in 2019 and the trend is projected to continue during the forecast period. A large number of antibiotics is in late phases of clinical pipeline trials and are likely to be commercialized between 2019 and 2025. Anticipated launch and adoption of antibiotics to address unmet medical needs in dystrophic epidermolysis bullosa treatment are expected to propel the segment during the forecast period.
Request for Analysis of COVID19 Impact on Dystrophic Epidermolysis Bullosa Treatment Market –
https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=79063
Dominant Dystrophic Epidermolysis Bullosa (DDEB) to be Highly Lucrative
Based on service provider, the global dystrophic epidermolysis bullosa treatment market has been bifurcated into dominant dystrophic epidermolysis bullosa (DDEB) and recessive dystrophic epidermolysis bullosa (RDEB). The dominant dystrophic epidermolysis bullosa (DDEB) segment dominated the global dystrophic epidermolysis bullosa treatment market due to large number of patients suffering from dominant dystrophic epidermolysis bullosa. According to the National EB Registry, the overall prevalence of EB is 11.07 per one million live births. The prevalence of DDEB and RDEB is 1.49 and 1.35 per one million live births, respectively.
Buy Market Report –
https://www.transparencymarketresearch.com/checkout.php?rep_id=79063<ype=S
Competition Landscape
Key players in the global dystrophic epidermolysis bullosa treatment market include Krystal Biotech, Castle Creek Biosciences, Inc., Abeona Therapeutics, Inc., Amryt Pharma plc, Wings Therapeutics, Phoenix Tissue Repair, InMed Pharmaceuticals, Inc., RegeneRx, and Holostem Terapie Avanzate S.r.l.
Browse More Reports by Transparency Market Research:
Browse More Trending Reports by Transparency Market Research:
Vaccines Market : The growth of the animal healthcare industry is significantly influenced by government efforts. The veterinary healthcare industry in China is likely to be driven by factors such as its mandatory immunization policy, availability of inexpensive veterinary vaccines, public awareness campaigns, and funding for R&D.
Dental Equipment Market : The number of people suffering from periodontal disease has been increased in the recent years. The Centers for Disease Control and Prevention (CDC) states that more than 47.2% of the population aged 30 years and above in the U.S. is dealing with some type of periodontal disease. As a result, the number of such patients seeking medical help is increasing. This factor is boosting the sales prospects in the dental equipment and maintenance market.
About Us:
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyse information. Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the unified market intelligence engine. Sign Up for a 7 day free trial!
Contact Us
Mr. Rohit Bhisey
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/
The post Dystrophic Epidermolysis Bullosa Treatment Market is projected to expand at a CAGR of ~5% from 2020 to 2030 appeared first on 360PRWire.
